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bstract
Pancreatic tumors are an increasingly common finding in abdominal imaging. Various kinds of pathologies of the pancreas are well known, but
t often remains difficult to classify the lesions radiologically in respect of type and grade of malignancy. Magnetic resonance imaging (MRI) is
he method of choice for the evaluation of pancreatic pathologies due to its superior soft tissue contrast. In this article we present a selection of less
ommon malignant and potentially malignant pancreatic neoplasms with their characteristic appearance on established MRI sequences with and
ithout contrast enhancement.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/
y-nc-sa/3.0/).ontents
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.  Introduction malignant as well as benign conditions. Pancreatic lesions areThe pancreas is a non-encapsulated organ located retroperi-
oneally. It is known to be affected by a broad spectrum of
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y-nc-sa/3.0/).ften discovered incidentally in asymptomatic patients, and if
he lesions cannot be classified further, clinical management
an be difficult. Routine imaging modalities for assessing the
ancreas include transabdominal ultrasound, endosonography,
ndoscopic retrograde cholangiopancreatography (ERCP) and
omputed tomography. However these examination tools are
imited in their ability to depict the soft tissue differences in
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etail. Thus, today, pre- and post gadolinium magnetic reso-
ance imaging (MRI) is the method of choice for the evaluation
f pancreatic pathologies. Morphology and histologic pattern of
alignant pancreatic tumors such as adenocarcinoma are well
escribed. In this article we present a selection of rare malig-
ant and potentially malignant pancreatic neoplasms with their
ypical appearance on MRI, since they have a better progno-
is than ductal adenocarcinoma. Hence knowledge of these rare
ntities is important with respect to diagnosis and treatment.
able 1 gives an overview of the different entities with their
haracteristic MR imaging features.
.  MRI/MRCP  protocol
Our routine pancreas MRI protocol includes a coronal
nd transverse T2 half-Fourier acquisition single-shot turbo
pin-echo (HASTE) sequence of the complete abdomen, trans-
erse diffusion weighted echoplanar (DWI-EPI) sequences,
1 FLASH sequences of the pancreas as well as MR-
holangiopancreatography (MRCP). Moreover, dynamic pre-
nd post-gadolinium images of the pancreas using transverse T1
D-VIBE sequences, and a transverse post-contrast T1 FLASH
D fat saturated sequence are acquired.
.1.  Intraductal  papillary  mucinous  neoplasm
Intraductal papillary mucinous neoplasm (IPMN) mostly
ccurs in the elderly with a male predominance [1]. Based on
he highest degree of cytoarchitectural atypia and invasiveness,
PMN can be classified according to the WHO as IPMN with
ow- to intermediate-grade dysplasia- previously called intra-
uctal papillary-mucinous adenoma, IPMN with high grade
ysplasia – previously called non-invasive intraductal papillary-
ucinous carcinoma, and IPMN with an associated invasive
arcinoma [1]. IPMN arise from the epithelium of the pancre-
tic ducts. The production of mucin results in dilatation of the
ain pancreatic duct or cystic dilatation of the branch ducts
2,3]. Most IPMN are discovered incidentally in asymptomatic
atients. If symptoms are present, they may include nausea,
bdominal pain or pancreatitis.
MRI shows pleomorphic or unilocular cystoid lesions, while
he tumor itself is usually not seen. Depending on the involve-
ent of main- or branch-ducts, IPMN can be categorized as
ain-duct, branch-duct or mixed type. All three types can be
ssociated with atrophy of the adjacent pancreatic parenchyma.
ain-duct involvement shows as dilatation of the main pancre-
tic duct (MPD) over 5 mm without other causes of obstruction
Fig. 1). Branch-duct IPMN appears as clustered, often grape-
ike cystoid lesions in the pancreas. The mucin-filled thus dilated
ranch ducts communicate with the healthy pancreatic duct
ystem. Consequently, BD-IPMN can be suspected if cystoid
esions with communication to the pancreatic ductal system are
resent [4]. The cystoid lesions, which appear hyperintense on
2-weighted images (WI) and hypointense on T1-WI, can be
ound throughout the whole pancreas and vary in size. Images
n the axial and coronal plane may reveal thin septae between the
s
n
a
cadiology Open 1 (2014) 49–59
esions. In rare cases, T2-WI may display solid portions within
he lesion.
Contrast enhanced images can also help identify solid compo-
ents such as small nodular lesions in the periphery of the lesions
mural nodules) (Fig. 1F). Diffusion weighted MR images are
ikely to predict the malignant potential of IPMN, with lower
pparent diffusion coefficient (ADC) values of the lesions in
PMN with high-grade dysplasia and invasive IPMN [5]. MRCP
hows lobulated cystoid lesions in BD-IPMN and a dilated MPD
n MD-IPMN, or both in mixed type-IPMN. Furthermore, it can
elp depict the relation of the cystoid lesions and the ductal sys-
em [6]. Intraductal mucin and solid components may be seen
s filling defects on MRCP.
Predictors for malignant potential have been identified,
nown as the Sendai criteria. With respect to imaging they
nclude cyst size more than 3 cm, involvement of the main pan-
reatic duct with dilatation over 5 mm, mural nodules or contrast
nhancing components and lymphadenopathy. IPMN with one
r more of those characteristics are highly likely to be malignant
nd surgical resection is recommended [4]. Otherwise, lesions
hould be monitored.
.2.  Mucinous  cystic  tumor
Mucinous cystic tumors (or neoplasms, MCN) usually occur
n women during the 4th and 5th decade of life [7]. They are
elatively rare, accounting for about 8% of surgically resected
ystic lesions of the pancreas [8]. MCN have malignant poten-
ial. According to the WHO and analogous to IPMN, they can be
ategorized as MCN with low- or intermediate-grade dysplasia-
reviously called mucinous cystadenoma, MCN with high-grade
ysplasia- previously called non-invasive mucinous cystadeno-
arcinoma, and MCN with an associated invasive carcinoma [1].
nvasive carcinoma is usually diagnosed in significantly older
atients than non-invasive MCN, suggesting a progression from
on-invasive to invasive MCN [9]. MCN are often discovered
ncidentally, and if symptoms occur, they are mostly related to
ass effects [10]. They are usually located the body or tail of the
ancreas [11]. In contrast to IPMN, MCN do not communicate
ith the pancreatic ductal system on MRCP [3]. Larger lesions
ay cause partial obstruction of the pancreatic duct due to mass
ffects.
On MRI, MCN present as unilocular or multilocular large
ysts. Thickness of cyst wall and septae is variable. MR
ignal of the cysts is usually low on T1-WI and high on
2-WI, but can vary, based on the content of the cysts
e.g., mucinous/hemorrhagic) [12]. After administration of
adolinium-chelate, on T1-weighted, fat-suppressed images the
all may show contrast enhancement while the cysts themselves
sually do not enhance [13] (Fig. 2). A large study found a cor-
elation between tumor size and malignancy: 92% of tumors
qual to or greater than 60 mm in size showed malignancy. Fur-
hermore, the presence of mural nodules or contrast-enhancing
oft tissue elements within the lesion is associated with malig-
ancy [9,14]. Focal calcifications, usually seen on MR images
s hypointense spots on all sequences and better detectable on
omputed tomography, can be another indication of malignancy
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Table 1
Overview of less common pancreatic malignancies and tumors with malignant potential in terms of WHO-classification, demographics and imaging features.
Type of lesion WHO-classification [1] Demographics MRI features
Intraductal papillary
mucinous neoplasm
Premalignant/malignant
epithelial tumors
Male predominance
Occurs mostly in the elderly [1]
Pleomorphic or unilocular cystoid lesions with connection
to the pancreatic ductal system
Dilatation of the MPD > 5 mm in main-duct-involvement
Lesions T1 hypointense, T2 hyperintense
Solid, contrast enhancing components suggest
malignancy [4,6]
Predictors for malignancy: Sendai criteria
ADC in benign/non-invasive lesions 2.95/2.67; lower in
malignant/invasive lesions (2.05/1.51) [5]
Mucinous cystic tumor Premalignant/malignant
epithelial tumors
Almost exclusively in women
(4th-5th decade) [7]
No communication with pancreatic ductal system [3]
Unilocular cysts in 80% of the cases, multilocular cysts in
20%.
Cysts T1 hypointense, T2 hyperintense
Variable thickness of cyst wall and septae [12]
Wall may show contrast enhancement [13]
Indicators of malignancy: cyst size >= 6 cm, focal
calcifications, presence of mural nodules or
contrast-enhancing soft tissue elements within the lesion
[14]
Acinar cell carcinoma Malignant epithelial
tumors
Accounts for 1–2% of all
pancreatic neoplasms
Typically occurs during 5th to 7th
decade of life
Male predominance [1]
Large, well defined exophytic lesion
Mostly solid; T1: low to intermediate signal intensity, T2:
intermediate to high signal intensity compared to
surrounding pancreas [20] [4]
Can contain cystic components/hemorrhage/necrotic
components/calcifications [20]
Heterogeneous contrast enhancement, less than the
surrounding parenchyma [20]
Solid pseudopapillary
neoplasm
Malignant epithelial
tumors
Mostly in young women (2nd-3rd
decades of life)
Metastases can be found in up to
15% of cases [23]
Rounded, often large mass
T1: low signal intensity, T2: intermediate to high signal
intensity
Small lesions homogeneous, large: often hemorrhagic,
cystic or necrotic, with calcifications or a T2 hypointense
or contrast enhancing capsule
Heterogeneous contrast enhancement with progressive
central filling and late enhancement of the capsule [24,25]
Neuroendocrine tumor Neuroendocrine
neoplasms
Usually in patients over 50 years
Slight male predominance [1]
T1: hypointense; T2: hyperintense compared to healthy
pancreas [13]
Hyperintense on contrast-enhanced T1-WI, especially
during arterial phase in dynamic studies [26]
Larger tumors sometimes with cystic or necrotic
components due to degeneration
Glucagonomas often with ring-like contrast-enhancement
ADC-values in small solid tumors lower (∼1.4) than in
normal pancreas [27]
PEComa Mesenchymal tumors Very rare mesenchymal neoplasm
of the pancreas
Female predominance [29]
T1: iso- to hypointense, T2: hyperintense compared to
skeletal muscle [31]
May exhibit hemorrhage [32]
Show contrast-enhancement [31]
Primary lymphoma Lymphomas Only 0.5% of all pancreatic
malignancies [34]
Mostly extranodal manifestations
of B cell non-Hodgkin’s
lymphoma [33,34]
Focal form: well-circumscribed homogeneous lesion; T1:
hypointense, T2: intermediate, heterogeneous signal
intensity.
Heterogeneous contrast enhancement, less than in
surrounding healthy pancreatic parenchyma [36]
Diffuse form: T1: decreased signal intensity, T2: variable
signal intensity [36,37]
Contrast enhancement homogeneous with or without
small spared spots [37]
Metastases Secondary tumors of the
pancreas
Incidence: pancreatic metastases
in 3–12% of patients with widely
metastatic disease in autopsy
studies and 2–5% in clinical
studies [40–43]
Small and well-defined masses [45]
Due to the variety of entities, appearance on MRI is
diverse
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Fig. 1. Mixed-type intraductal papillary mucinous neoplasm with invasive carcinoma in a 60-year-old woman. (A) Photograph shows characteristic fish-mouth
appearance of the ampulla of Vateri on endoscopy. (B) Coronal MRCP shows an irregular dilatation of the main pancreatic duct and a multicystic-appearing
lesion in the pancreatic head/uncinate process. (C) Axial T2-W HASTE sequence shows an irregular dilatation of the main pancreatic duct, representing the
main-duct component, and cystoid lesions in the pancreatic head, representing branch-duct components. (D) T2-W HASTE sequence in the axial plane shows a
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esion of the pancreatic head/uncinate process. (F) Fat-suppressed T1-WI in the
ypointense, multiloculated cystoid mass of the pancreatic head, partially enhan
15]. Due to their malignant potential, surgical resection is the
ethod of choice in treatment of MCN.
.3.  Acinar  cell  carcinoma
Acinar cell carcinoma (ACC) is a rare malignant epithelial
eoplasm with an exocrine differentiation. ACC accounts for
–2% of all pancreatic neoplasms. It typically occurs during late
dulthood (5th–7th decade) with a male predilection [16]. A sec-
nd peak in age distribution can be found in childhood [17]. Up to
0% of patients with ACC present with metastatic disease [18].
linical symptoms are rather variable and nonspecific. However,
ymptoms such as adiponecrosis or arthritis, which are related
o pancreatic enzyme production, and symptoms due to mass
ffects and metastases may occur.
a
n
pl T2-W HASTE sequence shows a well-defined, multiloculated, hyperintense
 plane obtained after intravenous administration of gadolinium-chelate shows a
and with nodular, solid appearing parts, pointing to malignancy
Only few studies deal with radiological findings in ACC.
ost ACC arise in the pancreatic head. Average size at the
ime of diagnosis is large, in one study up to 10 cm [19]. Mor-
hologically, ACC present as well-defined large oval or round
asses with an exophytic growth pattern. The solid parts of
he tumors present with low to intermediate signal intensity on
1-WI and intermediate to high signal intensity on T2-WI com-
ared to the surrounding normal pancreas, of which it is sharply
emarcated [20]. Signal intensity can be heterogeneous due
o hemorrhage, necrotic components or, rarely, calcifications.
ystic components can be seen in larger lesions. On contrast-
nhanced MRI, enhancement is heterogeneous. Since the lesions
re usually hypovascular, the contrast-enhancing solid compo-
ents may enhance less than the surrounding healthy pancreatic
arenchyma [20,21], which is not in line with our example,
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Fig. 2. Mucinous cystic neoplasm in a 42-year-old woman. (A) Photograph shows gross appearance of the 7 cm × 6 cm × 4 cm measuring unilocular cyst with fibrous
capsule filled with light brown material containing mucin, granulation tissue and inflammatory infiltrates as well as hemorrhagic portions. (B) Axial T1-WI shows a
well-circumscribed round heterogeneous mass in the pancreatic tail. Hyperintense parts represent hemorrhage. (C) Axial T2-WI shows a hyperintense heterogeneous
lesion with complex internal architecture; hypointense parts representing granulation tissue and inflammatory infiltrates. (D) Coronal fat suppressed T1-WI after
intravenous administration of gadolinium-chelate shows a hypointense, heterogeneous mass with a thick surrounding capsule with marked enhancement.
Fig. 3. Acinar cell carcinoma in a 63-year-old woman. (A) Axial T1-WI reveals a well-defined isointense lesion in the pancreatic body with a small hypointense
center, representing a cystic portion. (B) T2-WI in the axial plane shows an exophytic growing lesion in the pancreatic body with an intermediate signal intensity
compared to the surrounding normal pancreas and a hyperintense, cystic component. (C) Fat-suppressed T1-WI in the axial plane obtained early after intravenous
administration of gadolinium-chelate exhibiting atypical contrast behavior of the lesion, showing moderate homogeneous contrast enhancement of the lesion except
for the cystic portion. (D) Fat-suppressed T1-WI in the axial plane obtained later after intravenous administration of gadolinium-chelate reveals a decline in contrast
enhancement of the lesion.
54 D. Franz et al. / European Journal of Radiology Open 1 (2014) 49–59
Fig. 4. Solid pseudopapillary neoplasm (SPN) in a 17-year-old female with liver metastases (Fig. 4B–D: Courtesy of the Department of Diagnostic and Interventional
Radiology and Pediatric Radiology, Klinikum Schwabing, Munich, Germany). (A) Photograph shows macroscopic appearance of SPN of the pancreatic head. The
7 cm × 6 cm × 6 cm measuring tumor with a thin capsule shows an infiltration of the duodenal wall. The tumor itself is mainly solid with hemorrhages and few necrotic
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greas. (B) T2-W HASTE sequence shows a large, mostly homogeneous, well-defi
n the axial plane the lesion appears more heterogeneous, mostly hyperintense. 
howing a ring-like enhancement after contrast administration
Fig. 3). However, there are reports in the literature about hyper-
ascularity of ACC [22].
.4.  Solid  pseudopapillary  neoplasm
Solid pseudopapillary neoplasm (SPN) is a rare tumor with
ow-grade malignant potential, whose pathogenesis is not fully
nderstood. Synonyms are solid pseudopapillary tumor (SPT),
apillary and solid epithelial neoplasm, papillary cystic neo-
lasm, and (Gruber-)Frantz tumor. SPN mostly occur in young
omen (2nd–3rd decades of life). In general, SPN are of low-
rade malignancy but can develop metastases in up to 15% of
ases [23]. The lesions are usually solitary and often located in
he pancreatic body or tail. SPN can reach a remarkable size and
ften contain necrotic or hemorrhagic areas.
In terms of MR imaging findings, some characteristics dif-
er between smaller (<3 cm) and larger lesions [24]. In general,
R imaging shows a well circumscribed, rounded solid mass
ith low signal intensity on T1-WI and high to intermediate
ignal intensity on T2-WI. Cystic components can be present
nd are secondary to tumor degeneration. If lesions are pre-
ominantly cystic, signal intensity is closer to fluid on T2-WI.
maller SPN usually present homogeneously [25]. Large SPN
ften appear heterogeneous as they contain hemorrhagic, cystic
r necrotic parts, calcifications or a T2 hypointense or contrast-
nhancing capsule (Fig. 4). If hemorrhage, also secondary to
egeneration, is present, T1 signal within the lesion can be
s
c
nounded pancreatic mass with low signal intensity. (C) On fat-suppressed T2-WI
xial fat-suppressed T2-WI shows hyperintense liver metastasis (arrow).
ncreased. On gadolinium-enhanced images, SPN show hetero-
eneous enhancement with a gradual central filling, which is
elpful for differentiating SPN from lesions with early arte-
ial enhancement. If a capsule is present, it tends to show late
nhancement [23]. Regarding clinical management, complete
urgical excision is recommended as SPN are potentially curable
y resection of the primary tumor [23].
.5.  Neuroendocrine  tumors
Neuroendocrine tumors (or neuroendocrine neoplasms,
ET) of the pancreas arise from the pancreatic endocrine cells.
hey usually occur in patients over 50 years, with a slight
ale predominance. The tumor grading proposed by The World
ealth Organization (WHO) is based on mitotic count and Ki67
ndex. Neoplasms can be graded as neuroendocrine tumor (NET)
1 (carcinoid) or G2 and neuroendocrine carcinoma (NEC),
3 [1]. NET can present with typical clinical findings due to
ormone hypersecretion (“functioning” or “syndromic” NET)
r they can be non-functioning (or “nonsyndromic”). Depend-
ng on the type of hormone they secrete the most and the
linical presentation, syndromic tumors can be further classi-
ed as gastrinoma, insulinoma, somatostatinoma, VIPoma and
lucagonoma as well as rare types such as ACTHoma.On MRI, neuroendocrine tumors appear hypointense on fat
uppressed T1-WI compared to the surrounding healthy pan-
reas while they usually seem hyperintense compared to the
ormal pancreas on T2-WI [13]. Especially larger tumors may
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Fig. 5. Glucagonoma in a 69-year-old man. (A) Photograph shows gross appearance of a small white solid tumor of the pancreatic tail (circle). (B) Axial T2-W HASTE
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iequence shows a solitary hypointense mass of the pancreatic tail (arrow), poin
dministration of gadolinium-chelate exhibits contrast enhancement of the lesi
arrow).
ontain cystic or necrotic parts due to degeneration, which results
n a heterogeneous appearance. On post-contrast images, both
unctioning and non-functioning tumors show significant con-
rast enhancement. Enhancement may appear homogeneous,
iffuse heterogeneous, ring- or target-like, depending on the
omposition of the lesion. Cystic or necrotic components do
ot enhance and appear hypointense compared to the rest of the
esion on post-contrast T1-WI. Even in markedly cystic degen-
rated lesions, well-vascularized tissue can be found, pointing to
he diagnosis of NET [14]. On dynamic contrast enhanced stud-
es, NET enhance earlier and more intensely than the healthy
ancreatic parenchyma, thus appear hyperintense during the
rterial phase [26].
Metastases, for example in the liver, are hypervascular as
ell and therefore their contrast behavior is comparable to that
f the primary lesions. Rarely, tumors contain a lot of fibrous
issue hence show low signal intensity on T2-WI (Fig. 5) and less
ontrast enhancement [13]. DWI might be helpful in detecting
mall neuroendocrine tumors due to its higher image contrast;
DC-values tend to be lower than in the surrounding healthy
ancreas [27].
Insulinomas, as most of the neuroendocrine tumors, appear
ypointense on T1-WI and hyperintense on T2-WI. On
ost-gadolinium-images, small insulinomas usually enhance
omogeneously or, more rarely, target-like.
Gastrinomas demonstrate very low signal intensity on T1-
I and high signal intensity on T2-weighted fat suppressedmages. On contrast-enhanced images, they often show periph-
ral ring-like enhancement, as well as their liver metastases do.
s gastrinomas may occur outside the pancreatic parenchyma,
a
g
no fibrous tissue within the lesion. (C) Fat-suppressed T1-WI after intravenous
rrow). (D) On PET-MR fusion image the lesion is highly metabolically active
at-suppressed T2-WI can be helpful for their detection due to
heir hyperintensity compared to the surrounding suppressed fat
28].
.6.  Perivascular  epithelioid  cell  neoplasms
Perivascular epithelioid cell neoplasms (PEComas) of
he pancreas, also called clear cell “sugar” tumors, are
well-vascularized neoplasms (are) composed of large, clear,
pitheloid smooth-muscle cells”, as defined by The World
ealth Organization [1]. PEComas are very rare mesenchymal
eoplasms of the pancreas. There is a female predominance
29]. Due to its rarity, little is known about clinical and imag-
ng appearances, treatment and outcome of this disease. The
EComa family contains angiomyolipoma, clear cell “sugar”
umors and lymphangiomyomatosis, as well as a variety of
nusual visceral, intra-abdominal, and soft tissue/bone tumors
30].
Few is known about MRI-features of PEComas. In gen-
ral, PEComas mostly appear as well-defined soft tissue mass.
 recent study described MRI-features of malignant PECo-
as. They appeared iso- to hypointense compared to skeletal
uscle on T1-WI and heterogeneously hyperintense on T2-
I compared to skeletal muscle [31] (Fig. 6C). PEComas
ometimes show hemorrhagic parts [32]. Thus, if hemorrhage
s present, lesions seem heterogeneous in all sequences. The
bove-mentioned study also found that after administration of
adolinium-chelates, PEComas enhance avidly [31], which is
ot in line with our example (Fig. 6B).
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Fig. 6. Perivascular epithelioid cell neoplasm (PEComa) in a 53-year-old woman. (A) Photograph shows gross appearance of the small (1.4 cm × 0.9 cm × 0.5 cm)
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ancreatic body (arrow), exhibiting no contrast enhancement. (C) On axial T2-
n the axial plane (b = 600 s/mm2) shows diffusion restriction of the lesion (arro
.7.  Primary  pancreatic  lymphoma
Pancreatic lymphoma can be classified as either primary or
econdary lymphoma. Primary pancreatic lymphoma represents
nly 0.5% of all pancreatic malignancies. Less than 1% of all
rimary extralymphatic non-Hodgkin lymphoma can be found
n the pancreas and most of them are extranodal manifesta-
ions of B cell non-Hodgkin’s lymphoma [33,34]. Secondary
ymphoma results from peripancreatic lymphadenopathy and
s more frequent. Symptoms are nonspecific and include, e.g.
bdominal pain, weight loss, nausea and vomiting. Morphol-
gy of pancreatic lymphoma can be classified as either focal or
iffuse.
r
(
p
ig. 7. Primary pancreatic lymphoma in a 62-year-old man. (A) Axial T2-WI shows
right spots, representing necrotic tissue, next to areas with moderate signal intensity. 
dministration of gadolinium-chelate shows homogeneous enhancement with small sp
ail.o T1-W sequence shows homogeneously hypointense rounded lesion of the
he lesion (arrow) appears hyperintense compared to skeletal muscle. (D) DWI
On MRI, primary pancreatic lymphoma may present as a
ocal lesion without dilatation of the pancreatic duct or as diffuse
nlargement of the pancreas with narrowing of the pancre-
tic duct [35]. The focal form appears as well-circumscribed
omogeneous lesion with low signal intensity on T1-WI and
ntermediate, more heterogeneous signal intensity on T2-WI.
ontrast enhancement is heterogeneous, and less than in the sur-
ounding healthy pancreatic parenchyma [36]. The diffuse form
s characterized by mainly decreased signal intensity on T1-WI.
n T2-WI, signal intensity is variable. Contrast enhancement isather homogeneous with or without small spared spots [36,37]
Fig. 7). A hint to pancreatic lymphoma is the combination of a
ancreatic mass without dilatation of the main pancreatic duct
 a diffusely enlarged pancreas with inhomogeneous signal intensity with small
(B) Fat-suppressed FLASH T1-WI in the axial plane obtained after intravenous
ared spots. Infiltration of the peripancreatic fat is visible around the pancreatic
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Fig. 8. Widespread metastatic disease in malignant melanoma with pancreatic metastases in a 65-year-old man. (A) Coronal T2-W HASTE sequence shows a
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aell-defined rounded lesion in the pancreatic head with intermediate signal inten
een inferiorly to the stomach. (B) High resolution T2-WI reveals a hypointense
odule can be found medial to the left kidney.
nd peripancreatic lymphadenopathy without involvement of
nfrarenal levels [38].
.8.  Metastases
As the pancreas is a non-encapsulated organ, metastases of
arious malignant tumors can be found in the pancreas. Primary
umors from the kidney, lung, gastrointestinal tract as well as
ymphoma are the most common entities metastasizing to the
ancreas [39]. Other frequent entities are tumors of the breast,
hyroid gland, bones (osteosarcoma) and skin (melanoma). Still,
he incidence of metastases to the pancreas and the peripancre-
tic lymph nodes is only 3–12% of patients with widespread
etastatic disease in autopsy studies and 2–5% in clinical stud-
es, emphasizing their rarity. Often, pancreatic metastases are
ssociated with other extrapancreatic metastases since pancre-
tic metastases tend to develop rather late in the course of
alignant disease [40–43]. Metastases to the pancreas can be
ound anywhere within the pancreas (head/body/tail) [44]. Clues
hat may help differentiate metastases from primary pancreatic
umors include a prior history of malignancy, multiplicity of
esions and of course widespread metastatic disease. Pancreatic
etastases are usually small and well-defined masses [45].
Due to the variety of entities, appearance on MRI is diverse.
n this overview, we would like to present the MR appearance
f two of the entities: pancreatic metastases from renal cell
arcinoma (RCC) and from melanoma.
Pancreatic RCC metastases show a low signal on T1-WI,
hile signal intensity is high on T2-WI. On dynamic contrast
nhanced studies they show a strong enhancement in the early
hase, which may appear ring-like in larger lesions [41].
Pancreatic metastases of melanoma show characteristic sig-
al features on MRI caused by T1 and T2 shortening due to
he paramagnetic properties of melanin, resulting in high signal
ntensity on T1-WI and low to intermediate signal intensity on
2-WI [13] (Fig. 8). As lesions are T1-hyperintense, subtractionmaging can be helpful in identifying contrast enhancement. In
he amelanotic subtype of melanoma, due to the lower amount
f melanin, T1-signal in pre-contrast images tends to be iso- to
ypointense [46].
a
a
I
ilightly higher than the surrounding normal pancreas. Another metastasis can be
round the well-circumscribed, slightly hyperintense lesion. Another metastatic
.9.  Other  less  common  pancreatic  malignancies
Other less common pancreatic malignancies include primary
ancreatic sarcoma, serous cystadenocarcinoma, pancreatoblas-
oma, solitary fibrous tumor, pancreatic plasmocytoma and
esmoplastic round cell tumor.
Serous cystadenocarcinoma are far less frequent than benign
erous cystadenoma; only 1–3% of serous cystic neoplasms
re malignant. Less than 30 cases have been described in the
iterature. MRI shows a multicystic lesion with a honeycomb
ppearance, just as it can be found in serous cystadenoma. For
ifferentiation from serous cystadenoma, detection of local inva-
ion and distant metastases can be helpful as they are suggestive
f invasive carcinoma [47].
Pancreatoblastoma is a malignant tumor of childhood-
enerally occurring before ten years of age-metastasizing to
ymph nodes, liver and distant anatomic sites [48]. MRI shows
 well-defined lobulated mass which is usually located in the
ancreatic head, sometimes with cystic degeneration or calci-
cations [49]. On contrast enhanced MRI, they usually show
nhancement [50].
Solitary fibrous tumor is a very rare mesenchymal tumor
f the pancreas with malignant potential [51]. Only 10 cases
ave been described in the literature so far. Thus, very few is
nown about MR findings. Imaging findings described imply
 well circumscribed mass; tumor size in the reported cases
as 3 cm at minimum [52]. The masses may contain cystic
arts.
Primary pancreatic sarcoma is an extremely rare entity
ccounting for less than 0.1% of all pancreatic malignancies.
maging findings include a large, well-defined mass [53]. The
ass can have a contrast-enhancing capsule. In terms of MR-
orphology, knowledge is otherwise limited due to the paucity
f reports about imaging findings.
Plasmocytoma of the pancreas usually occurs in patients with
 history of multiple myeloma or other primary lesions and not as
 primary pancreatic lesion. Only two cases of primary pancre-
tic plasmocytoma have been reported in the literature [54,55].
maging shows a well-defined lobulated pancreatic mass which
s usually located in the pancreatic head [56].
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Desmoplastic small round cell tumors are extremely rare
nd highly aggressive neoplasms and occur in the pancreas in
xceptional cases [57]. Imaging studies show a large lobulated
eterogeneous mass [58]. Due to its rarity with only four cases
n the English literature, further characteristics on MRI studies
re not described.
.  Conclusion
A wide range of pancreatic malignancies and pancreatic
umors with malignant potential are known, and several of them
re quite rare, so little is known about their appearance on diag-
ostic imaging. In fact, many of them have characteristic features
hat are well demonstrated with MRI. MRI and its varieties have
he ability to depict soft tissues in detail thus allows excellent
valuation of the internal architecture of a lesion and its rela-
ion to the pancreatic parenchyma. However, there are typical
nd atypical appearances of rare pancreatic malignancies and
ancreatic tumors with malignant potential on MRI. Knowing
hose MRI features according to up-to-date literature facilitates
he initial diagnosis to help direct appropriate management in
atients with pancreatic lesions.
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